PJP News and Press, Invesco Dynamic Pharmaceuticals From 01/12/24

2024-01-12 11:27:00 ET Summary Horiba is likely undervalued due to it being under followed, and offers a rare combination of a quality business at an attractive price. The company has high market share in specialized devices in various industries, including automotive, process &am...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2024-01-06 08:15:00 ET Summary Global equity markets experienced a surge in 2023 driven by economic growth and investor confidence. US equity returns exceeded expectations despite concerns about higher rates, inflation, and geopolitical tension. In 2024, investors should focus...

2023-12-21 08:25:00 ET Summary Given strong recent market returns and another wave of capital inflows, the backdrop is probably not enough to lead to strong tactical performance from risk assets. The US has a more favorable demographic trend; its working-age population is expected...

2023-12-20 10:09:10 ET More on Invesco Exchange-Traded Fund Trust - Invesco Dynamic Pharmaceuticals ETF For further details see: Invesco Dynamic Pharmaceuticals ETF declares quarterly distribution of $0.1913

2023-12-20 06:19:00 ET Summary Can the Magnificent 7 continue to rally into 2024? How the Magnificent 7's rise compares to the dot-com bubble. Why the rise in tech stocks highlights shortcomings for the markets. The rise of the Magnificent 7 tech stocks has been a ke...

2023-12-09 03:00:00 ET Summary The global markets experienced high volatility in 2023 due to factors such as high interest rates, bank failures, and a surge in bond yields. The macro environment in 2024 is expected to be complex and interesting, with rewards for investors who are ...

2023-12-08 04:54:49 ET More on Pfizer, Astellas Pharma Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Astella...

2023-11-22 02:15:00 ET Summary Q3 earnings season had many familiar refrains relative to the year’s first two quarters. One difference was a return to positive earnings growth for the first time since Q3 2022. Not unlike the first two quarters of the year, earnings for ...